







Surgery for Acquired Cardiovascular Disease Thielmann et al
4
A
CDrognostic impact of previous percutaneous coronary
ntervention in patients with diabetes mellitus
nd triple-vessel disease undergoing coronary
rtery bypass surgery
atthias Thielmann, MD,a Markus Neuhäuser, PhD,b Stephan Knipp, MD,a Eva Kottenberg-Assenmacher, MD,c
































iFrom the Department of Thoracic and Car-
diovascular Surgery,a West German Heart
Center Essen, Essen, Germany; and the In-
stitute for Medical Informatics, Biometry,
and Epidemiologyb and the Department of
Anaesthesiology and Intensive Care Medi-
cine,c University Hospital Essen, Essen,
Germany.
Read at the 79th Scientific Sessions of the
American Heart Association, Chicago, Ill,
November 12-15, 2006.
Received for publication Feb 6, 2007; revi-
sions received April 10, 2007; accepted for
publication April 16, 2007.
Address for reprints: Matthias Thielmann,
MD, Department of Thoracic and Cardio-
vascular Surgery, West-German Heart Cen-
ter Essen, University Hospital Essen,
Hufelandstrae 55, 45122 Essen, Germany
(E-mail: matthias.thielmann@uni-due.de).
J Thorac Cardiovasc Surg 2007;134:470-6
0022-5223/$32.00
Copyright © 2007 by The American Asso-
ciation for Thoracic Surgery
Earn CME credits at at
http://cme.ctsnetjournals.orgt
doi:10.1016/j.jtcvs.2007.04.019
70 The Journal of Thoracic and Cardiobjectives: In the current era of stent usage, percutaneous coronary intervention is
ore frequently performed as the initial revascularization strategy in multivessel
isease before patients are finally referred to coronary artery bypass grafting. We
ought to determine whether previous PCI has a prognostic impact on outcome in
atients with diabetes mellitus and triple-vessel disease.
ethods: Between January 2000 and March 2006, 621 consecutive patients with
iabetes mellitus and triple-vessel disease undergoing isolated first-time coronary
rtery bypass grafting as the primary revascularization procedure (group 1) were
valuated for in-hospital mortality and major adverse cardiac events and compared
ith 128 patients with diabetes mellitus and triple-vessel disease treated during the
ame time period with previous percutaneous coronary intervention before coronary
rtery bypass grafting (group 2).
esults: All-cause in-hospital mortality was 2.9% in group 1 and 7.8% in group 2
odds ratio, 2.84; 95% confidence interval, 1.19-6.68; P  .02). In-hospital major
dverse cardiac events were identified in 6.1% and 14.1% (odds ratio, 2.51; 95%
onfidence interval, 1.32-4.73; P  .005), respectively. Risk-adjusted multivariate
ogistic regression analysis of previous percutaneous coronary intervention signif-
cantly correlated with in-hospital mortality (odds ratio, 2.87; 95% confidence
nterval, 1.29-6.37; P  .03) and major adverse cardiac events (odds ratio, 2.54;
5% confidence interval, 1.39-4.62; P  .01). After computed propensity score
atching based on 12 major preoperative risk factors to control selection bias,
onditional regression analysis confirmed previous percutaneous coronary interven-
ion to be associated with all-cause in-hospital mortality (odds ratio, 2.97; 95%
onfidence interval, 1.12-7.86; P  .03) and major adverse cardiac events (odds
atio, 2.46; 95% confidence interval, 1.18-5.15; P  .02) in these patients.
onclusion: Previous percutaneous coronary intervention before coronary artery
ypass grafting in patients with diabetes mellitus and triple-vessel disease indepen-
ently increases the risk for in-hospital mortality and major adverse cardiac events.
andomized control trials1-4 and recent real-world registries5-7 comparing
coronary artery bypass grafting (CABG) surgery with percutaneous coro-
nary intervention (PCI) still support CABG as the superior revascularization
trategy in terms of survival and reintervention rate in multivessel disease and
articularly in patients with diabetes mellitus and triple-vessel disease.7-9 However,
n the current era of stent usage, the number of patients with multivessel or
riple-vessel disease in whom PCI is initially performed and who might not get the
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CDption of receiving bypass surgery as their first-choice re-
ascularization treatment is rapidly increasing without any
quivalent scientific evidence. Subsequent CABG surgery
ith previous PCI, however, might not achieve the same
xcellent results, as thoroughly demonstrated in the litera-
ure. We therefore sought to determine whether previous
CI has a prognostic impact on surgical outcome in a
ingle-center, propensity score–matched, and risk-adjusted
ohort study, analyzing Bypass Angioplasty Revascularization
nvestigation–like patients10 with diabetes mellitus and tripl
essel disease who were finally referred to CABG therapy.
aterials and Methods
tudy Population
he patient cohort used for this study was drawn from the West
erman Heart Center cardiovascular database. This database pro-
pectively collects a comprehensive list of prespecified data points,
ith more than 1800 data items per patient, in all of the consec-
tive patients undergoing CABG surgery at our institution, includ-
ng demographic, clinical, and outcome data.
Within the database, patients were coded as having previous
tent implant procedures or not. The reported study cohort was
elected according to criteria of the Bypass Angioplasty Revascu-
arization Investigation.10 Patients included had diabetes mellit
nd triple-vessel coronary artery disease (70% stenosis) at their
nitial coronary revascularization therapy. Patients were excluded
f they had left main stenosis (50%), were treated within 24
ours of a myocardial infarction, or underwent an emergency,
oncomitant, or repeat surgical procedure. Patients were classified
nto one of the 2 groups depending on whether they had no
revious PCI procedure (group 1) or a previous PCI procedure as
he initial revascularization therapy (group 2) before first-time
lective CABG surgery. The association between previous PCI
efore CABG and postoperative in-hospital patient outcome was
nalyzed. The study was approved by the institutional review
oard. All of the patients had previously granted permission for
se of their medical records for research purposes.
tudy End Points and Definitions
ll study end points used in this analysis were prespecified. The
rimary study end point was all-cause in-hospital mortality. The
econdary end point was the major adverse cardiac event (MACE)
ate, including perioperative myocardial infarction (PMI), low
ardiac output syndrome (LCOS), cardiac death, and sudden car-
iac death during the postoperative hospitalization period. An
ndependent review of the medical records of the patients who died
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
LCOS  low cardiac output syndrome
MACEmajor adverse cardiac event
PCI  percutaneous coronary intervention
PMI  perioperative myocardial infarctionfter CABG surgery was performed, and cardiac versus noncardiac m
The Journal of Thoracicause of death was adjudicated.In-hospital death was defined as
eath after CABG during the index hospitalization. A PMI was
onsidered to have occurred if one of the following diagnostic
riteria were present: (1) a cardiac troponin I level of greater than
0.5 ng/mL after CABG, as previously described11; (2) a creatin
inase–MB level of 3 times greater than the upper normal level;
3) new persistent ST-segment or T-wave changes (Minnesota
ode 4-1, 4-2, 5-1, 5-2, or 9-2); or (4) the development of new
-waves (Minnesota code 1-1-1 to 1-2-7). LCOS was defined as a
ardiac index of 2.0 L · min1 · m2 or less or a systolic arterial
ressure of 90 mm Hg or less, despite high-dose inotropic support
intravenous dopamine, 8 g . kg1 · min1; dobutamine,
6 g . kg1 · min1; epinephrine, 0.1 g . kg1 · min1; or
orepinephrine, 0.1 g . kg1 · min1). Death was considered
ardiac if it was caused by PMI, significant cardiac arrhythmias, or
efractory LCOS. Sudden unexpected death occurring without
nother explanation was defined as sudden cardiac death.
erioperative Management
urgical revascularization was performed by using standard tech-
iques in all patients, as previously described.12 Heparin was
dministered to achieve an activated coagulation time of greater
han 400 seconds and protamine to reverse heparin according to
tandard practice. Patients who were receiving dual-antiplatelet
herapy with aspirin and clopidogrel before surgical intervention
ere perioperatively managed as follows: (1) maintenance of
spirin therapy until surgical intervention and routine intravenous
dministration of 500 mg of aspirin within 6 hours after surgical
ntervention followed by 100 mg/d thereafter and (2) discontinu-
tion of clopidogrel for a 2- to 5-day window in accordance with
he current American College of Cardiology/American Heart As-
ociation guidelines by withdrawing clopidogrel 72 hours before
urgical intervention at the earliest and restarting it within 48 hours
fter CABG at the latest.
tatistical Analysis
escriptive statistics are summarized for categoric variables as
requencies (percentages) and compared between groups by using
he Pearson 2 exact test. Continuous variables, expressed 
eans  standard deviation or median and interquartile range
15%75%) were compared between groups by using the Mann-
hitney U test or the Student t test. Univariate and multivariate
ogistic regression analyses were performed to identify preopera-
ive independent predictors for in-hospital death and MACEs.
hose variables identified by means of univariate regression with
P value of .1 or less for at least 1 study end point were added to
he multivariate regression model. A propensity score matching
n:m) was performed to control for selection bias as a result of
onrandom assignment to the groups.13 To be precise, we es-
ated propensity scores using logistic regression13 based on th
ollowing patient characteristics and major preoperative risk fac-
ors to calculate propensity scores: age, sex, obesity, hypertension,
yperlipidemia, left ventricular ejection fraction, renal disease,
revious myocardial infarction, antiplatelet therapy, chronic ob-
tructive pulmonary disease, peripheral vascular disease, and an-
ina class III or IV. We used the propensity scores for stratifica-
ion13; that is, patients with similar propensity scores atched into 20 sets (strata) of equal size. Such stratification is
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CDommon in medical research13 and is recommended according 
he results of Brookmeyer and colleagues.14 Based on the stratifie
ata, a conditional logistic regression analysis was used.15 All
tatistical analyses were performed with the SAS System, version
(SAS Institute, Inc, Cary, NC).
esults
he West German Heart Center Cardiovascular Database
dentified a total of 4853 patients who underwent isolated
rst-time CABG surgery from January 2000 through March
006. The following subgroups of patients were excluded
ccording to the study exclusion criteria: (1) patients with 1-
r 2-vessel disease at the time of recent PCI (n  351) or
efore CABG surgery (n  1019), (2) nondiabetic patients
n  3494), (3) patients with left main disease (n  1747),
4) patients with emergency status (n 323), or (7) patients
ith acute coronary syndromes (n  434). In addition, 16
atients with incomplete data on PCI status were excluded,
eaving 749 patients included for the present study. Of
hese, 621 patients with diabetes mellitus and triple-vessel
isease underwent isolated first-time CABG surgery as the
rimary revascularization therapy without having had pre-
ious PCI in group 1, whereas 128 patients with diabetes
ellitus and triple-vessel disease had PCI as the initial
evascularization therapy before undergoing isolated first-
ime CABG in group 2.
Preoperative characteristics of the patients are shown in
able 1. Patients did not differ according to most of
emographics, risk factors, and comorbidities, except for a
ignificantly higher number of patients with hypertension
nd a higher number of patients with preexisting renal
isease in group 2. Patient groups were also significantly
ifferent according to their history of previous myocardial
nfarctions and of course their history of previous PCI
rocedures. As a result, more group 2 patients had antiplate-
et therapy before surgical intervention with aspirin, clopi-
ogrel, or both compared with group 1 patients. The average
ime between last PCI and CABG was 8  11 months
Table 1). As a main indication for CABG surgery, p
rative coronary angiography presented 15% of group 2
atients with isolated in-stent restenoses, 25% with isolated
e novo coronary artery stenoses, and 60% with combined
n-stent restenoses and de novo coronary artery stenoses.
ccording to the type of stent used, 72% of group 2 patients
ad bare-metal stents, 12% had drug-eluting stents, and
6% had both bare-metal stents and drug-eluting stents.
ntraoperative results, such as cardiopulmonary bypass and
ortic crossclamp times, number of bypass grafts and distal
nastomoses, and mean bypass graft flows, did not differ
etween the groups.
The incidences of the primary and secondary study end
oints, as well as all other postoperative outcome data, are
resented in Figures 1 and 2 and Table 2. As a main 
he 2 study groups were different regarding all-cause in- e
72 The Journal of Thoracic and Cardiovascular Surgery ● Auguir
-
lt,
ospital death (P  .02) and in-hospital MACEs (P  .005,
igure 1). Furthermore, group 2 patients had a higher 
ence of all secondary end points, such as sudden cardiac
eath (P  .04), cardiac death (P  .006), LCOS (P 
003), and PMI (P  .002), compared with group 1 patients
Figure 2). This was accompanied by a significantly lo
ength of intensive care unit stay (P  .04) and a higher
ncidence of postoperative rethoracotomy (P  .02, Table 2)
A logistic regression analysis model was constructed to
ABLE 1. Preoperative patient characteristics
Group 1,
without previous
PCI (n  621)
Group 2,
with previous
PCI (n  128) P value
emographics
Age (y) 66 9 67 9 .44
Sex, female 165 (27) 33 (26) .91
Body weight (kg) 83 16 83  13 .67
isk factors and
comorbidities
Diabetes mellitus 621 (100) 128 (100) 1.00
Dietary treated 110 (18) 26 (20) .53
Medically treated 319 (51) 58 (45) .24
Insulin treated 192 (31) 43 (34) .60
Hypertension 511 (82) 114 (85) .07
Hyperlipidemia* 458 (74) 103 (80) .12
Obesity (BMI 30) 333 (54) 76 (59) .24
Smoking past 2 mo 89 (14) 23 (18) .34
Smoking past 1 y 239 (38) 45 (35) .49
History of stroke 73 (12) 19 (15) .37
COPD 111 (18) 28 (22) .32
Peripheral vascular
disease
109 (18) 24 (19) .80
Renal disease† 97 (16) 32 (25) .01
ardiac history
Angina CCS III-IV 53 (9) 9 (7) .61
MI 4 wk prior 211 (34) 57 (45) .03
Previous PCI 0 (0) 219 (171) .0001
Time interval,
PCI-CABG
— 8 11 —
LVEF (%) 56 15 56  13 .73
edication
Antiplatelet therapy 333 (54) 94 (73) .001
-Blocker 449 (72) 101 (75) .13
Statins 424 (68) 103 (80) .08
ACE inhibitor 415 (67) 94 (73) .15
Nitrates 325 (52) 66 (52) .92
ata are presented as means  standard deviation or number (percent-
ge). PCI, Percutaneous coronary intervention; BMI, body mass index;
OPD, chronic obstructive pulmonary disease; CCS, Canadian Cardiovas-
ular Society; MI, myocardial infarction; CABG, coronary artery bypass
rafting; LVEF, left ventricular ejection fraction; ACE, angiotensin-converting
nzyme. *Serum cholesterol level of 200 mg/dL or greater or low-density
ipoprotein level of greater than 130 mg/dL. †Serum creatinine level of
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A
CDral univariate factors were found to be predictive for death
Table 3). After risk adjustment in a multivariate log
egression model, age and a history of previous PCI were
ound to be independently associated with in-hospital death
Table 3). As an independent preoperative predictor 
n-hospital MACEs, only a history of previous PCI was
dentified after risk adjustment in the multivariate regression
nalysis model (Table 4).
In an attempt to further correct for and minimize selec-
ion bias, a computed propensity score matching (n:m) of
he 2 study groups based on 12 major preoperative risk
actors was performed. Even after propensity score match-
ng, a conditional logistic regression analysis confirmed
atients with a history of previous PCI to be significantly
ssociated with an increased risk for in-hospital death (odds
atio, 2.97; 95% confidence interval, 1.12-7.86; P  .028)
nd in-hospital MACEs (odds ratio, 2.46; 95% confidence
nterval, 1.18-5.15; P  .016).
igure 1. Incidence of death and major adverse cardiac events
MACE) during hospital stay. P, Overall significance between the
roups.
igure 2. Incidence of secondary end points during hospital stay.
, Overall significance between the groups; PCI, percutaneous
oronary intervention; LCOS, low cardiac output syndrome PMI,
erioperative myocardial infarction. r
The Journal of Thoraciciscussion
he present study is the first to examine the prognostic
mpact of previous PCI procedures in the thus-far surgical
omain of a high-risk subset of patients with coronary artery
isease with diabetes mellitus and triple-vessel disease. The
ain result of the study is that patients with diabetes mel-
itus and triple-vessel disease who undergo isolated first-
ime elective CABG and were treated initially by means of
CI with coronary stent graft placement carry a higher risk
or in-hospital mortality and MACEs compared with the
ame subgroup of patients without previous PCI before
ABG.
Recent randomized controlled trails1-4 and large-scale
eal-world registries5-7 of PCI versus CABG performed 
he current stent era still support CABG surgery as the
uperior and preferred revascularization strategy, deriving a
urvival benefit for CABG and reducing the necessity for
urther coronary reintervention procedures in patients with
ultivessel disease or left main disease and particularly in
atients with diabetes mellitus and triple-vessel diseas16
ABLE 2. Intraoperative and postoperative characteristics
Group 1,
without previous
PCI (n  621)
Group 2,
with previous
PCI (n  128) P value
ntraoperative data
CPB time (min) 109 36 111  37 .86
ACC time (min) 70 23 71  26 .94
Reperfusion time (min) 34 16 35  15 .93
No. of grafts 3.0 0.8 3.0  0.9 .42
No. of distal
anastomoses
3.6  1.2 3.5  1.3 .21
Mean graft flow (mL/
min)
54  31 54  32 .56
ostoperative data
Ventilation time (h) 8 (7-12) 8 (7-11) .95
IABP support 31 (5.0) 8 (6.3) .52
ICU stay (d) 1 (1-3) 2 (1-4) .04





85 (14) 21 (16) .41
Ventricular arrhythmia 30 (4.8) 8 (6.3) .51
Renal failure (dialysis) 51 (8.2) 12 (9.4) .73
Stroke 12 (1.9) 1 (0.8) .49
Re-exploration for
bleeding
14 (2.3) 8 (6.3) .02
CPR 18 (2.9) 7 (5.5) .17
ata are presented as means  standard deviation, number (percentage),
r median and interquartile range (15%-75%). PCI, Percutaneous coronary
ntervention; CPB, cardiopulmonary bypass; ACC, aortic crossclamp; IABP,
ntra-aortic balloon pump; ICU, intensive care unit; CPR, cardiopulmonary
esuscitation.
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A
CDlthough these findings are conterminously reflected in the
urrent American College of Cardiology/American Heart
ssociation guidelines, which favor CABG surgery over
CI in these patients, substantial variability exists in prac-
ice patterns among individual hospitals, suggesting a lack
f clinical consensus. Thus, in turn, PCI is currently being
erformed more often in patients with severe multivessel
isease and even in patients with diabetes mellitus and
riple-vessel disease who were considered unsuitable in the
ast.17 At the same time, recent randomized clinical -
ls,1-4 although PCI friendly by enrolling only highly -
ected patient cohorts,18 indicate that probably more th
0% to 40% of the patients treated by means of PCI with
ABLE 3. Univariate and multivariate logistic regression an
Univariate an
Odds ratio (95% CI)
ge (y) 1.1 (1.0-1.1)
ex, female 2.3 (1.1-5.0)
besity (BMI 30) 1.0 (0.6-1.6)
VEF (%) 0.9 (0.9-1.0)




ngina class III-IV 1.2 (0.5-2.8)
revious MI 0.9 (0.4-2.0)
enal disease 1.4 (0.5-3.5)
roup 1, without previous PCI Reference
roup 2, with previous PCI 2.9 (1.3-6.4)
I, Confidence interval; BMI, body mass index; LVEF, left ventricular eje
nfarction; PCI, percutaneous coronary intervention.
able 4. Univariate and multivariate logistic regression an
Univariate an
Odds ratio (95% CI)
ge (y) 1.0 (1.0-1.1)
ex, female 1.6 (0.9-2.9)
besity (BMI 30) 1.1 (0.8-1.4)
VEF (%) 1.0 (0.9-1.0)




ngina class III-IV 2.2 (1.1-4.6)
revious MI 1.8 (1.0-3.2)
enal disease 2.1 (1.1-3.9)
roup 1, without previous PCI Reference
roup 2, with previous PCI 2.5 (1.4-4.6)
I, Confidence interval; BMI, body mass index; LVEF, left ventricular eje
nfarction; PCI, percutaneous coronary intervention.
74 The Journal of Thoracic and Cardiovascular Surgery ● Auguore complex coronary lesions and multivessel disease
ave symptom recurrence and restenosis, requiring further
oronary revascularization therapy. Hence today’s CABG
urgery is faced with a rapidly and cumulatively increasing
umber of patients with multivessel disease, in whom pre-
ious PCI procedures with coronary stenting have initially
een performed before patients are finally referred to CABG
urgery.
The clinical importance and prognostic significance of
atients with a history of PCI that might be interfering with
utcome when surgical treatment is subsequently required
ave become recognized recently. At first, evidence
merged in the former times of angioplasty, showing that
is of variables associated with all-cause in-hospital death
s Multivariate analysis
P value Odds ratio (95% CI) P value
.01 1.1 (1.0-1.1) .04











.01 2.5 (1.3-5.8) .03
fraction; COPD, chronic obstructive pulmonary disease; MI, myocardial
is of variables associated with in-hospital MACEs
s Multivariate analysis
P value Odds ratio (95% CI) P value
.02 1.0 (0.9-1.1) .39
.09 1.4 (0.7-2.9) .29
.51 — —
.07 1.0 (0.9-1.0) .37




.03 2.0 (0.9-4.4) .09
.04 1.7 (1.0-3.1) .07
.02 1.6 (0.8-3.4) .22
Reference Reference Reference
.002 2.5 (1.2-4.9) .01
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A
CDatients with initial percutaneous transluminal coronary an-
ioplasty and subsequently undergoing CABG had a poorer
ong-term survival.19 There was also recent evidence th
CI itself adversely affects outcome in repeated PCIs20 and
lso in several clinical studies of noncardiac surgical pa-
ients, in whom the risk for major adverse events after
urgical intervention significantly increased with previous
CI.21-23 More recently, we demonstrated that multiple P
rocedures before CABG significantly impair patient 
ospital outcome,12 and there is also recent evidence t
revious PCI increases the risk of death in the short te24
s well as the risk of symptom recurrence and MACE rate
n the midterm,25 after coronary bypass surgery. Potenti
nderlying pathomechanisms for MACEs after PCI have
een identified, such as several independent predictors and
isk factors of early and long-term stent thrombosis, includ-
ng the use of more than one stent, use of long stents, use of
tents placed at a bifurcation, a history of stent thrombosis,
ncomplete revascularization, diabetes mellitus, renal fail-
re, low ejection fraction, and premature antiplatelet ther-
py discontinuation, especially after implantation of drug-
luting stents.26 Conversely, postoperative blood loss an
leeding complications caused by continuation of antiplate-
et therapy might lead to increased transfusion and platelet
equirements, which in turn might cause acute stent throm-
osis. Furthermore, numerous additional perioperative patho-
echanisms among patients with previous PCI under-
oing CABG might exist, which have been studied less
horoughly and are as yet largely unknown. There is a
rowing body of evidence that coronary stents are causing
rterial wall injury, leading to dysfunctional and denuded
oronary endothelium with chronic inflammatory response
nd platelet and neutrophil adhesion, which in turn are
ausing adverse cardiovascular events.27-29 In addition, i
he diameter of the stented vessel is less than 2.5 to 3.0 mm,
he risk of thrombosis is much higher, and the bypass graft
as to be inserted more distally, which in turn adversely
ffects coronary run-off and the patency rate of the inserted
raft.27,30
Although the present study was nonrandomized and ret-
ospective in design and the generalizability of our experi-
nce at a single tertiary care medical center might not
xtend to all CABG-performing clinical centers, as the first
tudy, it clearly indicates that the increasing practice of
nitial PCI before surgical intervention significantly in-
reases the risk of subsequent CABG in a well-defined
isk-adjusted and propensity score-matched subgroup of
atients with diabetes mellitus and triple-vessel disease.
urther clinical research and multicenter outcome studies
re needed to investigate and confirm the short-term and
ong-term effects of PCI procedures with coronary stenting
efore CABG surgery.
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